Share Twitter LinkedIn Facebook Email Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read